Clinical trial shows by 2030 that GLP-1 receptor agonists significantly reduce osteoarthritis symptoms
Santé et médecineOne-OffManifold MarketsFerméSans KYCDonnées de résolution vérifiéesAssez bien calibréCe marché s'est résolu: Yes (77.7%)
Résolu: 3 oct. 2026, 01:08
Résolution vérifiée par le fournisseur
CoinRithm dispose d'éléments du fournisseur pour le gagnant et l'heure de règlement de ce marché.
Alerte qualité des donnéesDonnées obsolètes
Données au 3 oct. 2026, 07:01 UTC · politique pm-quality-4
Chronologie des Probabilités
Yes77.7%
No22.299999999999997%
Gagné
Perdu
Marchés Associés
Questions liées pour le contexte, et non une comparaison de contrats équivalents.
What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Manifold MarketsWhat will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 24 months?
Manifold MarketsWill Ozempic/GLP-1 Agonists become an issue with a clear partisan divide in the US in the next 5 years?
Manifold MarketsWill human tooth regrowth clinical trials succeed?
Manifold MarketsTdi-11861 (a fast-acting male contraceptive) approved for human clinical trials by the end of 2026?
FutuurHow many clinical trials will have started in Prospera by Dec 31, 2026?
FutuurRègles
Resolution criteria
- This market will resolve to "Yes" if, by December 31, 2030, a peer-reviewed clinical trial demonstrates that GLP-1 receptor agonists significantly reduce osteoarthritis symptoms in humans.
- The trial must be published in a reputable medical journal and show statistically significant improvements in osteoarthritis symptoms compared to a control group.
- The primary outcome measures should include validated assessments of pain, physical function, and/or structural changes in the affected joints.
- If no such study is published by the specified date, the market will resolve to "No".
- If such a study sets out to investigate this and finds no significant reduction of such symptoms before market end date the market also resolves "No".
